Bionano genomics news.

Bionano Genomics shares will start to get out of their current rut. It’ll start breaking out of its current $5-$6 per share trading range. After that, it’ll be up to other factors to help fuel ...Mar 13, 2023 · Bionano Genomics, Inc. +1 (858) 888-7610. [email protected]. Investor Relations: Amy Conrad. Juniper Point. +1 (858) 366-3243. [email protected]. Bionano CEO and president Dr. Erik Holmlin ... Mar 31, 2022 · UPDATE - Bionano Announces Preliminary Q1 2023 Results and Business Updates. Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million, which would represent an estimated increase of 28% to 32% over Q1 2022. Installed base of Saphyr® systems reached 259 as of March 31, 2023, which represents growth of the installed base by 19 ... Bionano’s Stratys system for OGM offers increased throughput capabilities to address the needs of mid and high-volume users. The throughput of the Stratys instrument is up to four times greater than that of Bionano’s Saphyr instrument, it is compatible with the latest G2 chemistry and has a potential sample-to-answer time of 3 …Find real-time BNGO - Bionano Genomics Inc stock quotes, company profile, ... No recent news for Bionano Genomics Inc. Today’s Trading. Previous close: 1.59: Today’s open: 1.55:

Albino parakeets are those that exhibit a mutation in the color-producing portion of their genome. The gene that causes the mutation is called the ino gene. However, because there are two different basic colorations for parakeets—blue and...SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting, held earlier today.The final voting results will be available in a current report on Form 8-K, which will be filed with the SEC within 4 days of the meeting. “We appreciate …

GuruFocus Research November 8, 2023 at 6:19 PM · 4 min read Bionano Genomics Inc ( NASDAQ:BNGO) sees a 29% increase in Q3 2023 revenue, reaching …News Release Details « Back. Bionano Genomics Reports First Quarter 2022 Financial Results and Highlights Recent Business Progress. May 05, 2022 | PDF Version - 80% year-over-year revenue growth in Q1 2022 - Achieved all Q1 2022 ELEVATE! milestones - Strong balance sheet with $216.5 million in cash, cash equivalents, and …

GuruFocus Research November 8, 2023 at 6:19 PM · 4 min read Bionano Genomics Inc ( NASDAQ:BNGO) sees a 29% increase in Q3 2023 revenue, reaching …Bionano Genomics. May 9, 2023 at 4:01 PM · 17 min read. Bionano Genomics. Q1 2023 revenue was $7.4 million, which represents a 30% increase over Q1 2022. Installed base of 259 Saphyr® systems ...SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from researchers at the German Cancer Consortium (DKTK) showing the utility of optical genome mapping (OGM) and whole-exome sequencing (WES) in better understanding the mutational landscape of …Sep 28, 2023 · SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first peer-reviewed benchmarking study to compare optical genome mapping (OGM) to the current global standard in molecular analysis of constitutional genetic disorders, chromosomal microarray analysis (CMA).

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine.

We believe this technology-centric view is holding us back from the answers to critical questions around the origin, diagnosis, severity and treatment of cancer and genetic disease. We believe the way to move forward is an inclusive one that reveals what other tools miss and unifies data across technologies into one view to maximize the ...

A-smart is Bionano’s second Chinese OEM partner to obtain approval from NMPA for the Company’s optical genome mapping (OGM) solutions. NMPA issued two approvals to A-smart: one for Bionano’s G2 direct label and stain (DLS) DNA labeling kit and one for Bionano’s G2 SP bone marrow aspirate (BMA) DNA isolation kit.News Release Details « Back. Bionano Genomics Reports Second Quarter 2022 Financial Results and Highlights Recent Business Progress. Aug 04, 2022 | PDF Version - 73% year-over-year revenue growth in Q2 2022 - Achieved all 1H 2022 ELEVATE! milestones - Strong balance sheet with $187.3 million in cash, cash equivalents, and …Dec 31, 2022 · SAN DIEGO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported certain unaudited preliminary financial and commercial highlights for the fourth quarter and fiscal year ended December 31, 2022. The Company’s full results for the fourth quarter and the fiscal year ended December 31, 2022 are not yet available. Third quarter 2023 non-GAAP operating expense was $31.8 million, compared to $26.3 million in the third quarter of 2022 and $34.6 million in the second quarter of 2023. Third quarter 2023 non-GAAP ...August 04, 2023 at 12:01 pm EDT. SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023.

Aug 7, 2023 · Bionano Genomics (NASDAQ: BNGO) effected a 1-for-10 reverse stock split and announced that it will publish quarterly earnings on Aug. 9. Shares opened this morning at $4.73 each, a market ... Third quarter 2023 non-GAAP operating expense was $31.8 million, compared to $26.3 million in the third quarter of 2022 and $34.6 million in the second quarter of 2023. Third quarter 2023 non-GAAP ...Jul 6, 2021 · About Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business ... Jun 30, 2023 · Bionano participated at key cytogenetic conferences, including the European Hematology Association (EHA) 2023 Congress, the European Human Genetics (ESHG) 2023 Conference, the European Association for Cancer Research (EACR) 2023 Congress and the International Society for Stem Cell Research (ISSCR) Annual Meeting 2023. OGM was featured in 37 ... About Bionano Genomics Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.

Bionano Genomics SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company …

Bionano Genomics. SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a …SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the launch of Bionano Laboratories, a new organization that combines Bionano’s optical genome mapping (OGM) data services with the clinical testing services previously offered by Lineagen, and the launch of Bionano Laboratories’ first OGM-based laboratory developed test (LDT).Get the latest Bionano Genomics, Inc. (BNGO) stock news and headlines to help you in your trading and investing decisions.SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that on September 18, 2023, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted an inducement award consisting of a non-qualified stock option to purchase 106,000 …Stock Performance. Shares of Bionano Genomics were trading at $1.63 as of November 06. Over the last 52-week period, shares are down 92.9%. Given that these returns are generally negative, long ...Following the downgrade, the current consensus from Bionano Genomics' five analysts is for revenues of US$40m in 2023 which - if met - would reflect a huge 53% increase on its sales over the past ...News Release Details « Back. Bionano Genomics Reports First Quarter 2022 Financial Results and Highlights Recent Business Progress. May 05, 2022 | PDF Version - 80% year-over-year revenue growth in Q1 2022 - Achieved all Q1 2022 ELEVATE! milestones - Strong balance sheet with $216.5 million in cash, cash equivalents, and …

Aug 1, 2023 · SAN DIEGO , Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023.

The current analyst consensus has Bionano Genomics, Inc. losing around 45 cents a share in FY2023 as sales rise nearly 30% to $35.7 million. Revenue growth is projected to accelerate by over 70% ...

Read the latest breaking news from Bionano Genomics. Find out if Bionano Genomics is biased and reliable and if their media bias is left, center, or right. Get access to our best features. Get Started. Enable Notifications Browser Extension Show Grayscale Images. Wednesday, November 22, 2023 Set Location. US Edition. Home. …Oct 10, 2023 · NEW YORK – Bionano Genomics this week executed a new round of layoffs, GenomeWeb has learned. According to information obtained by GenomeWeb from former employees who wished to remain anonymous, the workforce reduction appears to impact around 60 employees, although company executives declined to comment. According to data from Benzinga Pro, BioNano Genomics is trading lower by 1.6% to $1.23. BNGO has a 52-week high of $4.35 and a 52-week low of $1.16. Photo via Shutterstock.Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform ...See Bionano Genomics, Inc. (BNGO) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.SAN DIEGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting with a broad range of content covering the utility of optical genome mapping (OGM) for solid tumor and hematological malignancy cancer research, including scientific …Albino parakeets are those that exhibit a mutation in the color-producing portion of their genome. The gene that causes the mutation is called the ino gene. However, because there are two different basic colorations for parakeets—blue and...Bionano Genomics (BNGO 4.40%) Q2 2023 Earnings Call Aug 09, 2023, 4:30 p.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Good day, and ...

NEW YORK – Bionano Genomics said on Friday afternoon that the company is executing a 1-for-10 reverse stock split of its issued and outstanding common stock. The move will take effect at 5 p.m. Eastern Daylight Time on August 4, and the company's common stock will begin trading on a split-adjusted basis commencing upon market …9 Mei 2023 ... News Release Details. « Back. Bionano Reports First Quarter 2023 ... Bionano Genomics is a provider of genome analysis solutions that can ...Bionano announced today that it has priced a financing to raise an aggregate of $80.0 million in a registered offering and concurrent private placement of senior secured convertible notes due 2025... SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million …Instagram:https://instagram. masterworks investing reviewbooks on optionsexploring antarcticapattern day trading td ameritrade Get Bionano Genomics Inc (BNGO.A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments. voo distributionsgle 63 coupe Automate Data Display for Powerful Insights. VIA software amplifies the story of your data by automatically generating powerful visualizations for enhanced variant contextualization across multiple variant types happening in the same genomic region. VIA allows you to drill down to single chromosome, gene, and nucleotide levels for deeper analysis. About Bionano Genomics Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. how to buy femff stock The average price point forecasted by analysts for Bionano Genomics Inc (BNGO) is $12.33, which is $10.7 above the current market price. The public float for BNGO is 38.09M, and currently, short sellers hold a 17.35% ratio of that float. The average trading volume of BNGO on November 27, 2023 was 888.80K shares. Top 5 EV Tech Stocks to Buy for ...Aug 30, 2023 · SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Nature Communications demonstrating the utility of optical genome mapping (OGM) as an alternative to karyotyping (KT) and chromosomal microarray (CMA) for the evaluation of CRISPR-Cas9 edited human induced pluripotent stem cell (iPSC) lines in order to uncover possible pathogenic ... SAN DIEGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting with a broad range of content covering the utility of optical genome mapping (OGM) for solid tumor and hematological malignancy cancer research, including scientific …